申请人:AstraZeneca AB
公开号:US06833387B1
公开(公告)日:2004-12-21
The use of a 3-substituted indole compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof; X is CH2 or SO2 and R1, R2, R3, R4, R5, R6 and R7 are certain specified organic moieties, for use in the preparation of a medicament for the inhibition of monocyte chemoattractant protein-1 and/or RANTES induced chemotaxis. Pharmaceutical compositions containing certain compounds of formula (I) and novel compounds of formula (I) are also described and claimed.
使用式(I)的3-取代吲哚化合物或其药学上可接受的盐、酰胺或酯;X为CH2或SO2,R1、R2、R3、R4、R5、R6和R7为特定指定的有机基团,用于制备用于抑制单核细胞趋化蛋白-1和/或RANTES诱导趋化的药物。还描述和声明了含有式(I)的某些化合物和式(I)的新化合物的药物组合物。